Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.

Lu B, Al-Ramahi I, Valencia A, Wang Q, Berenshteyn F, Yang H, Gallego-Flores T, Ichcho S, Lacoste A, Hild M, Difiglia M, Botas J, Palacino J.

Nat Neurosci. 2013 May;16(5):562-70. doi: 10.1038/nn.3367.

Functional Impact of Sydenham's Chorea: A Case Report.

Gimeno H, Barry S, Lin JP, Gordon A.

Tremor Other Hyperkinet Mov (N Y). 2013;3. pii: tre-03-128-3381-1. doi: 10.7916/D8WQ03GV.

Difficulty modifying a sustained motor response in prodromal Huntington's disease.

Mickes L, Wixted JT, Peavy GM, Jacobson MW, Goldstein JL, Corey-Bloom J.

J Clin Exp Neuropsychol. 2013;35(1):35-40. doi: 10.1080/13803395.2012.742039.

Multiple Aspects of Gene Dysregulation in Huntington's Disease.

Moumné L, Betuing S, Caboche J.

Front Neurol. 2013 Oct 23;4:127. doi: 10.3389/fneur.2013.00127. Review.

Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.

Lin JT, Chang WC, Chen HM, Lai HL, Chen CY, Tao MH, Chern Y.

Mol Cell Biol. 2013 Mar;33(5):1073-84. doi: 10.1128/MCB.01434-12.

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease.

Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR.

J Med Genet. 2013 Oct;50(10):696-703. doi: 10.1136/jmedgenet-2013-101796.

An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.

Wang N, Lu XH, Sandoval SV, Yang XW.

J Huntingtons Dis. 2013;2(4):443-51. doi: 10.3233/JHD-130074.

Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Cepeda C, Galvan L, Holley SM, Rao SP, André VM, Botelho EP, Chen JY, Watson JB, Deisseroth K, Levine MS.

J Neurosci. 2013 Apr 24;33(17):7393-406. doi: 10.1523/JNEUROSCI.2137-12.2013.

Deficits in a Simple Visual Go/No-go Discrimination Task in Two Mouse Models of Huntington's Disease.

Oakeshott S, Farrar A, Port R, Cummins-Sutphen J, Berger J, Watson-Johnson J, Ramboz S, Howland D, Brunner D.

PLoS Curr. 2013 Nov 7;5. pii: ecurrents.hd.fe74c94bdd446a0470f6f905a30b5dd1. doi: 10.1371/currents.hd.fe74c94bdd446a0470f6f905a30b5dd1.

Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease.

McCollum MH, Leon RT, Rush DB, Guthrie KM, Wei J.

Brain Res. 2013 Jun 26;1518:91-103. doi: 10.1016/j.brainres.2013.04.030.

The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease.

Van Liew C, Gluhm S, Goldstein J, Cronan TA, Corey-Bloom J.

Psychiatry. 2013 Winter;76(4):323-35. doi: 10.1521/psyc.2013.76.4.323.

Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Lee J, Hwang YJ, Kim KY, Kowall NW, Ryu H.

Neurotherapeutics. 2013 Oct;10(4):664-76. doi: 10.1007/s13311-013-0206-5. Review.

Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease.

Benraiss A, Toner MJ, Xu Q, Bruel-Jungerman E, Rogers EH, Wang F, Economides AN, Davidson BL, Kageyama R, Nedergaard M, Goldman SA.

Cell Stem Cell. 2013 Jun 6;12(6):787-99. doi: 10.1016/j.stem.2013.04.014.

Expression of expanded CAG transcripts triggers nucleolar stress in Huntington's disease.

Tsoi H, Chan HY.

Cerebellum. 2013 Jun;12(3):310-2. doi: 10.1007/s12311-012-0447-6.

Head drops are also observed in advanced Huntington disease.

Spampinato U, Debruxelles S, Rouanet M, Lafoucrière D, Bader B, Danek A, Tison F, Goizet C.

Parkinsonism Relat Disord. 2013 May;19(5):569-70. doi: 10.1016/j.parkreldis.2013.01.012. No abstract available.